• 1
    Tefferi A,Vardiman JW. Myelodysplastic syndromes. N Engl J Med 2009; 361: 18721885.
  • 2
    Morel P,Hebbar M,Lai JL, et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: A report on 408 cases. Leukemia 1993; 7: 13151323.
  • 3
    Toyama K,Ohyashiki K,Yoshida Y, et al. Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: A multicentric study in Japan. Leukemia 1993; 7: 499508.
  • 4
    Solé F,Espinet B,Sanz GF, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Hematol 2000; 108: 346356.
  • 5
    Sole F,Luno E,Sanzo C, et al. Identification of novel cytogenetic markers with prognostic significance in a series of 968 patients with primary myelodysplastic syndromes. Hematologica 2005; 90: 11681178.
  • 6
    Schanz J,Steidl C,Fonatsch C, et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011; 29: 19631970.
  • 7
    Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008; 87: 515526.
  • 8
    Greenberg P,Cox C,LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 20792088.
  • 9
    Haase D,Germing U,Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 2007; 110: 43854395.
  • 10
    Pozdnyakova O,Miron PM,Tang G, et al. Cytogenetic abnormalities in a series of 1029 patients with primary myelodysplastic syndromes: A report from the US with a focus on some undefined single chromosomal abnormalities. Cancer 2008; 113: 33313340.
  • 11
    Cordoba I,González-Porras JR,Nomdedeu B, et al. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cancer 2012: 118; 127133.
  • 12
    Schanz J,Tüchler H,Solé F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. JCO 2011; 35: 6394.
  • 13
    Sanada M,Uike N,Ohyashiki K, et al. Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms. Leukemia 2007; 21: 992e7.
  • 14
    Slovak ML,O'Donnell M,Smith DD, et al. Does MDS with der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single institutional analysis of clinical/pathologic features compared with -7/del(7q) MDS. Cancer Genet Cytogenet 2009; 193: 7885.
  • 15
    Dewald GW,Broderick DJ,Tom WW, et al. The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet 1985; 18: 110.
  • 16
    Shaffer LG,Slovak ML,Campbell LJ. An International System for Human Cytogenetic Nomenclature. Basel, Switzerland: S. Karger; 2009.
  • 17
    Vardiman JW,Thiele J,Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114: 937951.